Show simple item record

Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial.

dc.contributor.authorGleeson, M
dc.contributor.authorHawkes, E
dc.contributor.authorCunningham, D
dc.contributor.authorChadwick, N
dc.contributor.authorCounsell, N
dc.contributor.authorLawrie, A
dc.contributor.authorJack, A
dc.contributor.authorSmith, P
dc.contributor.authorMouncey, P
dc.contributor.authorPocock, C
dc.contributor.authorArdeshna, K
dc.contributor.authorRadford, John A
dc.contributor.authorMcMillan, A
dc.contributor.authorDavies, J
dc.contributor.authorTurner, D
dc.contributor.authorKruger, A
dc.contributor.authorJohnson, P
dc.contributor.authorGambell, J
dc.contributor.authorLinch, D
dc.date.accessioned2016-10-12T13:34:39Z
dc.date.available2016-10-12T13:34:39Z
dc.date.issued2016-08-01
dc.identifier.citationRituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial. 2016: Br J Haematolen
dc.identifier.issn1365-2141
dc.identifier.pmid27477167
dc.identifier.doi10.1111/bjh.14287
dc.identifier.urihttp://hdl.handle.net/10541/619944
dc.description.abstractWe performed a subgroup analysis of the phase III UK National Cancer Research Institute R-CHOP-14 versus R-CHOP-21 (two- versus three-weekly rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) trial to evaluate the outcomes for 50 patients with World Health Organization 2008 classified primary mediastinal B-cell lymphoma identified from the trial database. At a median follow-up of 7·2 years the 5-year progression-free survival and overall survival was 79·8% and 83·8%, respectively. An exploratory analysis raised the possibility of a better outcome in those who received R-CHOP-14 and time intensification may still, in the rituximab era, merit testing in a randomised trial in this subgroup of patients.
dc.languageENG
dc.language.isoenen
dc.rightsArchived with thanks to British journal of haematologyen
dc.titleRituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial.en
dc.typeArticleen
dc.contributor.departmentThe Royal Marsden Hospital, London and Surrey, UKen
dc.identifier.journalBritish Journal of Haematologyen
dc.description.collectionLymphoma Research Teamen
html.description.abstractWe performed a subgroup analysis of the phase III UK National Cancer Research Institute R-CHOP-14 versus R-CHOP-21 (two- versus three-weekly rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) trial to evaluate the outcomes for 50 patients with World Health Organization 2008 classified primary mediastinal B-cell lymphoma identified from the trial database. At a median follow-up of 7·2 years the 5-year progression-free survival and overall survival was 79·8% and 83·8%, respectively. An exploratory analysis raised the possibility of a better outcome in those who received R-CHOP-14 and time intensification may still, in the rituximab era, merit testing in a randomised trial in this subgroup of patients.


This item appears in the following Collection(s)

Show simple item record